Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.66
-0.50 (-3.53%)
At close: Nov 20, 2026, 4:00 PM EST
13.70
+0.04 (0.29%)
After-hours: Nov 20, 2026, 7:30 PM EST
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Mineralys Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $43.56. The average 1-year stock price forecast is 218.89% higher than the current stock price, while the lowest is $19 (+39.09%) and the highest is $56 (+309.96%).
Price Target: $43.56 (+218.89%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Mineralys Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $56 | Buy | Reiterates | $56 | +309.96% | Nov 9, 2026 |
| UBS | UBS | Hold Reiterates $29 → $19 | Hold | Reiterates | $29 → $19 | +39.09% | Nov 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $55 | Buy | Maintains | $55 | +302.64% | Nov 6, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 5, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 5, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
84.31M
EPS This Year
-4.58
from -2.29
EPS Next Year
-2.66
from -4.58
EPS and Forward PE are based on non-GAAP adjusted numbers.